Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

Eli Lilly on Friday announced that it has received FDA approval for its bone-strengthening drug raloxifene, sold under the brand-name Evista, to reduce the risk of breast cancer for postmenopausal women at high risk of the disease and postmenopausal women with osteoporosis, the Wall Street Journal reports (Wall Street Journal, 9/15). [click link for full article]

More: continued here